Compare · CERC vs PVAC
CERC vs PVAC
Side-by-side comparison of Cerecor Inc. (CERC) and Penn Virginia Corporation (PVAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- CERC operates in Health Care, while PVAC operates in Energy - the two are in different parts of the market.
- PVAC is the larger of the two at $1.16B, about 4.1x CERC ($286.1M).
- Company
- Cerecor Inc.
- Penn Virginia Corporation
- Price
- $2.92-1.85%
- $30.69-2.97%
- Market cap
- $286.1M
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Oil & Gas Production
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Cerecor Inc.
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Penn Virginia Corporation
Penn Virginia Corporation, an independent oil and gas company, engages in the onshore exploration, development, and production of crude oil, natural gas liquids, and natural gas in the United States. It primarily operates wells in the Eagle Ford Shale field in South Texas. As of December 31, 2020, it had total proved reserves of approximately 126 million barrels of oil equivalent; and 532 gross productive wells, as well as owned approximately 98,300 gross acres of leasehold and royalty interests. Penn Virginia Corporation was incorporated in 1882 and is headquartered in Houston, Texas.
Latest CERC
- SEC Form 3 filed by new insider Maher Illya Keith
- Cerecor Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)
- SEC Form 4 filed by Bruhn Suzanne Louise
- SEC Form 4 filed by Gutry Phil
- SEC Form 4 filed by Miller Joseph M
- SEC Form 4 filed by Persson Magnus
- SEC Form 4 filed by Kaplan Gilla
- SEC Form 4 filed by Cola Michael F
- SEC Form SC 13G filed by Cerecor Inc.
Latest PVAC
- Ranger Oil's Borrowing Base Increased by 20%
- S&P Global Ratings Upgrades Ranger Oil
- Penn Virginia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Ranger Oil Provides Third Quarter 2021 and Rebranding Update
- Penn Virginia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Juniper Capital Iii Gp, L.P.
- SEC Form 4 filed by Juniper Capital Ii Gp, L.P.
- SEC Form 4 filed by Geiser Edward
- SEC Form 3: New insider Burnett Richard Alan claimed ownership of 19,284 shares
- Penn Virginia Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits